These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 13678917)

  • 1. Angiographic predictors of adverse outcomes in the modern interventional era.
    White CJ
    J Am Coll Cardiol; 2003 Sep; 42(6):989-90. PubMed ID: 13678917
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
    Ross MJ; Herrmann HC; Moliterno DJ; Blankenship JC; Demopoulos L; DiBattiste PM; Ellis SG; Ghazzal Z; Martin JL; White J; Topol EJ
    J Am Coll Cardiol; 2003 Sep; 42(6):981-8. PubMed ID: 13678916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 4. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 6. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Nursing; 1999 Dec; 29(12):34-9; quiz 40. PubMed ID: 10797693
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
    Ambrose JA; Doss R; Geagea JM; Hawkey MC; Duvuri S; Giedd K; Dominguez A; Coppola J; Nguyen TH; Palla V; Barua RS; Saha DC
    Am J Cardiol; 2001 May; 87(10):1231-3: A8. PubMed ID: 11356410
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
    Dangas G; Colombo A
    Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Albuquerque A
    Rev Port Cardiol; 2001 Sep; 20(9):927-8. PubMed ID: 11763604
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 16. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
    JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    Osman F; Qaisar S; El Gaylani N; Pitt M
    JAMA; 2005 Oct; 294(13):1616-7; author reply 1617-8. PubMed ID: 16204658
    [No Abstract]   [Full Text] [Related]  

  • 18. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 19. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    De Luca L; Sardella G
    JAMA; 2005 Oct; 294(13):1617; author reply 1617-8. PubMed ID: 16204659
    [No Abstract]   [Full Text] [Related]  

  • 20. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.